Page 1

November 4 , 2021 Checkpoint Therapeutics Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results WALTHAM , Mass . , Nov. 04 , 2021 ( GLOBE NEWSWIRE ) -- Checkpoint Therapeutics , Inc. ( " Checkpoint " ) ( NASDAQ : CKPT ) , a clinical - stage immunotherapy and targeted oncology company , today announced financial results for the third quarter ended September 30 , 2021 . James F. Oliviero , President and Chief Executive Officer of Checkpoint , stated , “ The third quarter brought a marked increase in our preparation activities for a potential Biologics License Application submission for cosibelimab next year , as we eagerly await the top - line results from our registration - enabling study in metastatic cutaneous squamous cell carcinoma . Additionally , during the quarter we made substantial progress towards the near- term initiation of our Phase 3 registration - enabling trial for cosibelimab in first - line metastatic non - small cell lung cancer . ” Mr. Oliviero continued , “ We believe the coming months could be transformational for our company , as we continue to hire the key personnel to position us favorably for the transition into a fully - integrated biopharmaceutical company focused on the goal of offering cancer therapies that provide better patient outcomes while delivering significant value to the future of healthcare . " Financial Results : • Cash Position : As of September 30 , 2021 , Checkpoint's cash and cash equivalents totaled $ 60.2 million , compared to $ 65.1 million at June 30 , 2021 and $ 40.8 million at December 31 , 2020 , a decrease of $ 4.9 million for the quarter and an increase of $ 19.4 million year - to - date . • R & D Expenses : Research and development expenses for the third quarter of 2021 were $ 9.4 million , compared to $ 2.5 million for the third quarter of 2020 , an increase of $ 6.9 million . The increase in research and development expenses is primarily attributable to an increase in clinical trial and manufacturing related expenses for cosibelimab . Research and development expenses for the third quarters of 2021 and 2020 each included $ 0.2 million of non - cash stock expenses . • G & A Expenses : General and administrative expenses for the third quarter of 2021 were $ 1.9 million , compared to $ 2.4 million for the third quarter of 2020 , a decrease of $ 0.5 million . General and administrative expenses for the third quarter of 2021 included $ 0.6 million of non - cash stock expenses , compared to $ 1.3 million for the third quarter of 2020 . • Net Loss : Net loss attributable to common stockholders for the third quarter of 2021 was $ 11.3 million , or $ 0.14 per share , compared to a net loss of $ 4.9 million , or $ 0.09 per share , in the third quarter of 2020. Net loss for the third quarter of 2021 included $ 0.8 million of non - cash stock expenses , compared to $ 1.5 million for the third quarter of 2020 .